Domainex Ltd was established in 2001 and operates from sites in London and Cambridge UK. In May 2007 Domainex merged with NCE Discovery at Cambridge to form a new integrated Company with capabilities in biology and chemistry.
Our biology division offers technologies designed to clone and express challenging genes, or functional domains of the gene products, to deliver high-quality recombinant protein.
Our chemistry division, NCE Discovery, offers experienced computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins.
Our drug development division seeks to exploit these technologies and expertise within internal projects. Our internal programmes are exclusively focussed on nucleotide binding domains (NBDs) found in several important therapeutic targets.
